



Pharmaceuticals Limited

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,
Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad - 500 034, Telangana, INDIA.
Tel : +91-40-2525 9999, Fax : +91-40-2525 9889
CIN : L24239TG1987PLC008066
Email: info@smspharma.com, www.smspharma.com

Date: 10th February, 2023

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

Symbol: SMSPHARMA

Dear Sir/Madam,

Sub: Newspaper cuttings of published financial results for third quarter and nine months ended December 31, 2022

Pursuant to Regulation 47 read with Regulation 33, we enclose copies of the newspaper Advertisements published in The Financial Express (English), and in Andhra Prabha (Telugu), on 10th February, 2023 regarding the un-audited Standalone & Consolidated Financial Results for the third quarter and nine months ended December 31, 2022.

This information is also being made available on the website of the Company www.smspharma.com.

Please take the above intimation on your records.

Thanking you

Yours faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma
Company Secretary

1. The above Un-Audited Financial Results for the Quarter approved by the Board of Directors at their meetings held of Statutory Auditors.
2. The Consolidated Results include results of all subsidiary Limited, KSoft Systems Inc.
3. The Company and its subsidiaries operate in 4 major Seg Payment & Credit Services.
4. The above is an Extract of the detailed format of quarterly Obligations and Disclosure Requirements) Regulations, 201 www.bseindia.com and Company's website www.virinchi.c
5. Standalone Financial Information of the Company is as un

Particulars	31 Ur
Total Income	
Profit before Tax	
Profit for the Period	
Date: 09.02.2023 Place: Hyderabad	



Manali
Registered
No. 88, M

**EXTRACT FROM T
FOR THE QUARTE**

Particulars	
Total Income	
Net Profit for the period (before Tax, Exceptio and Extraordinary Items)	
Net Profit for the period before Tax (after Exce and Extraordinary Items)	



SMS PHARMACEUTICALS LIMITED

CIN :L24239TG1987PLC008066,

Regd. Office : Plot No. 72, H.No: 8-2-334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills,
Hyderabad TG 500034, Phone: 040-35359999, Fax:040-25259889,
Email: complianceofficer@smspharma.com, www.smspharma.com

Extract of Financial Results for the third quarter and nine months ended 31st December, 2022

(₹ in Lakhs)

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended 31.12.2022	Nine months ended 31.12.2022	Quarter ended 31.12.2021	Year ended 31.03.2022	Quarter ended 31.12.2022	Nine months ended 31.12.2022	Quarter ended 31.12.2021	Year ended 31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations (net)	15,101.86	37,625.51	12,338.34	52,507.20	15,101.86	37,625.51	12,338.34	52,507.20
2	Profit from Ordinary Activities before Tax	641.85	(509.30)	1,656.18	6,865.47	666.76	(484.39)	1,632.69	6,849.91
3	Profit from Ordinary Activities after Tax (after Extraordinary Items)	502.76	(399.00)	1,050.61	6,803.65	376.43	(1,056.99)	896.26	6,221.99
4	Total Comprehensive Income for the quarter (comprising profit/Loss for the quarter (after tax) and other comprehensive items)	504.03	(395.46)	1,045.26	6,807.58	378.74	(1,050.37)	892.66	6,230.00
5	Equity Share Capital (Face value of share: ₹ 1/- each)	846.52	846.52	846.52	846.52	846.52	846.52	846.52	846.52
6	Reserves (excluding Revaluation Reserve as per Balance Sheet) ₹ 1/- each	-	-	-	48,529.50	-	-	-	46,182.34
7	Earnings per share (before extraordinary items - (Not annualized)	-	-	-	-	-	-	-	-
	a) Basic/Diluted (in ₹)	0.59	(0.47)	1.24	8.04	0.44	(1.25)	1.07	7.35

Notes: 1. The above Standalone and consolidated Financial Results have been reviewed and recommended by the Audit Committee Meeting held on 08th February, 2023 and approved by the Board of Directors in their meetings held on 9th February, 2023 and Statutory Auditors of the Company have carried out a Limited Review.

2. These results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed Under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3. The above is an extract of detailed format of quarterly / half yearly financial results filed with the stock exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of quarterly / half yearly financial results are available on the website of the Stock Exchanges of BSE www.bseindia.com (ID: 532815), NSE (www.nseindia.com) (Symbol:SMSPHARMA) and companies website (www.smspharma.com).

By and on behalf of Board of Directors
SMS Pharmaceuticals Limited

Sd/-

Ramesh Babu Potluri (DIN: 00166381)
Chairman and Managing Director

Place: Hyderabad
Date: 09.02.2023



VEEJAY LAKSHMI ENGINEERING WORKS LIMITED

Regd. Office: Sengalipalayam, NGGO Colony P.O., Coimbatore 641022
Email Id: compsec@veejaylakshmi.com Website: www.veejaylakshmi.com
CIN :L29191TZ1974PLC000705

STATEMENT OF UNAUDITED RESULTS FOR THE QUARTER / NINE MONTHS PERIOD ENDED 31/12/2022 Rs. in lakhs

Sl. No.	PARTICULARS	STANDALONE	CONSOLIDATED
------------	-------------	------------	--------------

